InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

November 14, 2023

Read More »

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

November 2, 2023

Read More »

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

October 26, 2023

Read More »

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

October 24, 2023

Read More »

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

October 24, 2023

Read More »

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

September 29, 2023

Read More »

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

September 22, 2023

Read More »

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 7, 2023

Read More »

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

July 21, 2023

Read More »

InMed Provides Update on BayMedica Rare Cannabinoid Business

July 20, 2023

Read More »

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

June 22, 2023

Read More »

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

June 1, 2023

Read More »

InMed to Participate in Upcoming Virtual Investor Events

May 24, 2023

Read More »

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

May 18, 2023

Read More »

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 15, 2023

Read More »

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

March 28, 2023

Read More »

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023

Read More »

InMed to Participate in Upcoming Investor Events

March 7, 2023

Read More »

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023

Read More »

InMed Submits Form 12b-25

February 9, 2023

Read More »